196. Does Cefepime Provide an Advantage over Ceftriaxone in the Treatment of Bloodstream Infections due to Escherichia coli, Klebsiella pneumoniae group, Klebsiella oxytoca, and Proteus spp. if CTX-M is not Detected by Rapid Molecular Testing?

BACKGROUND: The BIOFIRE® Blood Culture Identification 2 (BCID2) Panel (bioMérieux) allows for rapid detection of pathogens and antibiotic resistance genes in bloodstream infections (BSIs), including CTX-M, an Extended Spectrum Beta-Lactamase. Atrium Health’s treatment algorithm recommends cefepime (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynn Hammer, Katie, Hamm, Alyssa, Welch, Stephanie N, Smith, Jordan R, Ann Medaris, Leigh, Boger, Michael S, Williamson, Julie E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677336/
http://dx.doi.org/10.1093/ofid/ofad500.269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677336/
http://dx.doi.org/10.1093/ofid/ofad500.269

Ejemplares similares